Lmcg Investments LLC Sells 63,413 Shares of Johnson & Johnson (NYSE:JNJ)

Lmcg Investments LLC lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 72.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,749 shares of the company’s stock after selling 63,413 shares during the quarter. Lmcg Investments LLC’s holdings in Johnson & Johnson were worth $3,435,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in JNJ. Fred Alger Management LLC lifted its position in shares of Johnson & Johnson by 6.1% during the second quarter. Fred Alger Management LLC now owns 42,968 shares of the company’s stock worth $6,280,000 after purchasing an additional 2,488 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Johnson & Johnson by 38.6% during the second quarter. AQR Capital Management LLC now owns 3,350,292 shares of the company’s stock worth $489,176,000 after purchasing an additional 932,477 shares in the last quarter. Ameriprise Financial Inc. lifted its position in shares of Johnson & Johnson by 5.5% during the second quarter. Ameriprise Financial Inc. now owns 14,374,397 shares of the company’s stock worth $2,100,427,000 after purchasing an additional 754,200 shares in the last quarter. Drucker Wealth 3.0 LLC acquired a new position in Johnson & Johnson in the second quarter valued at approximately $612,000. Finally, Daymark Wealth Partners LLC lifted its holdings in Johnson & Johnson by 2.0% in the second quarter. Daymark Wealth Partners LLC now owns 304,204 shares of the company’s stock valued at $44,462,000 after buying an additional 6,033 shares during the period. 69.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently weighed in on JNJ shares. Guggenheim increased their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 16th. Stifel Nicolaus cut their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a report on Thursday. Bank of America cut their price objective on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a report on Thursday. Finally, Wolfe Research started coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price on the stock. Nine research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $170.06.

Insider Transactions at Johnson & Johnson

In other news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Trading Up 0.9 %

Shares of NYSE:JNJ opened at $146.58 on Friday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The company’s fifty day simple moving average is $148.10 and its 200 day simple moving average is $156.05. The firm has a market cap of $352.91 billion, a price-to-earnings ratio of 21.21, a PEG ratio of 2.52 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22,438,500 billion. During the same period in the previous year, the business earned $2.29 EPS. The company’s revenue was up 5.3% compared to the same quarter last year. As a group, research analysts forecast that Johnson & Johnson will post 9.95 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.38%. Johnson & Johnson’s payout ratio is currently 71.78%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.